ENDLOS-TURBO CALL - ELI LILLY & CO | Market Closed - Deutsche Boerse AG 01:04:48 26/06/2024 am IST | ||
| 50.23 EUR | +1.95% |
|
| Current month | +20.25% | ||
| 1 month | +21.80% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
More news
| Date | Price | Change |
|---|---|---|
| 25/24/25 | 50.23 | +1.95% |
| 24/24/24 | 49.27 | +1.15% |
| 21/24/21 | 48.71 | +0.45% |
| 20/24/20 | 48.49 | -1.84% |
| 19/24/19 | 49.4 | +0.86% |
Delayed Quote Deutsche Boerse AG
Last update June 26, 2024 at 01:04 am IST
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | DZ BANK |
| WKN | DJ0QNV |
| ISIN | DE000DJ0QNV0 |
| Date issued | 28/03/2023 |
| Strike | 364.3 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 0.78 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 50.82 € |
|---|---|
| Lowest since issue | 0.27 € |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
904.6
USD
Average target price
860.5
USD
Spread / Average Target
-4.87%
- Stock Market
- Certificates
- Certificat
